Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-05-30
2006-05-30
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C530S388100, C530S388150, C530S388220, C424S142100, C424S143100
Reexamination Certificate
active
07052693
ABSTRACT:
The present invention provides an antibody or peptide which immunologically reacts with human VEGF receptor Flt-1 and cells in which human VEGF receptor Flt-1 is expressed on the cell surface and an antibody or peptide which inhibits binding of human VEGF to human VEGF receptor Flt-1. It also provides a means for the diagnosis or treatment of diseases in which their morbid states progress by abnormal angiogenesis, such as proliferation or metastasis of solid tumors, arthritis in rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, psoriasis, and the like.
REFERENCES:
patent: 5750078 (1998-05-01), Shitara et al.
patent: 5807548 (1998-09-01), Shitara et al.
patent: 5830470 (1998-11-01), Nakamura et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5874255 (1999-02-01), Nakamura et al.
patent: 5874542 (1999-02-01), Rockwell et al.
patent: 6018032 (2000-01-01), Koike et al.
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 0 882 799 (1998-12-01), None
patent: WO 95 21868 (1995-08-01), None
Bird et al., “Single-Chain Antigen-Binding Proteins”. Science. vol. 242, Oct. 1988, pp. 423.426.
Mitola et al., “Tat-Human Immunodeficiency Virus-1 Induces Human Monocyte Chemotaxis by Activation of Vascular Endothelial Growth Factor Receptor-1”, Blood, vol. 90, No. 4, (Aug. 15, 1997, pp. 1365-1372.
Webber et al., “Preparation and Characterization of a Disulfide-Stabilized Fv Fragment of the Anti-TAC Antibody: Comparison with its Single-Chain Analog”, Molecular Immunology, vol. 32, No. 4, pp. 249-258, 1995.
Shibuya et al., “Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosin Kinase Gene (flt) Closely Related to thefmsFamily”, Oncogene (1990), 5, 519-524.
Shibuya et al., “Nucleotide sequence and expression of a novel human receptor”, Oncogene (1990), 5, 519-524.
Seetharam et al., “A unique signal transduction from FLT cyrosine kinase, a receptor for vascular endothelial growth factor VEGF”, Oncogene (1995) 10, 135-147.
Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growthin vivo”, NATURE, vol. 362, Apr. 29, 1993, pp. 841-844.
De Vries et al., “Thefms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor”, Reports, Feb. 21, 1992, pp. 989-991.
Melnyk et al., “Vascular Endothelial Growth Factor Promotes Tumor Dissemination by a Mechanism Distinct from Its Effect on Primary Tumor Growth”, Cancer Research 56, pp. 921-924, Feb. 15, 1996.
Folkman et al., “Minireview: Angiogenesis”, The Journal of Biological Chemistry, vol. 267, No. 16, Issue of Jun. 5, pp. 10931-10934, 1992.
Masabumi Shibuya, “Role Of VEGF-FLT Receptor System In Normal And Tumor Angiogenesis”, Institute of Medical Science, University of Tokyo, Tokyo 108, Japan, pp. 281-317, 1995.
Senger et al., “Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid”, Science, vol. 219, Feb. 25, 1983, pp. 983-985.
Ferrara et al., “Pituitary Follicular Cells Secrete A Novel Heparin-Binding Growth Factor Specific For Vascular Endothelial Cells”, Biochemical and Biophysical Research Communications, vol. 161, No. 2, 1989, Jun. 15, 1989, pp. 851-858.
Leung et al., “Vascular Endothelial Growth Factor is Secreted Angiogenic Mitogen”, Science, pp. 1306-1309, Dec. 8, 1989.
Koch et al., “Vascular Endothelial Growth Factor A Cytokine Modulating Endothelial Function in Rheumatoid Arthritis”, Journal of Immunology, 1994, 152: 4149-4156.
Unemori et al., “Vascular Endothelial Growth Factor Induces Intersitial Collagenase Expression in Human Endothelial Cells”, Journal of Cellular Physiology 153: 557-562(1992).
Pepper et al., “Vascular Endothelial Growth Factor (VEGF) Induces Plasminogen Activators and Plasminogen Activator Inhibitor-1 in Microvascular Endothelial Cells”, Biochemical and Biophysical Research Communications, vol. 181, No. 2, 1991, Dec. 16, 1991, pp. 902-906.
Asahara et al., “Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on AngiogenesisIn Vivo”, Basic Research, Supplement II, Circulation, vol. 92, No. 9, Nov. 1, 1995, pp. 365-371.
Houck et al., “Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms”, The Journal of Biological Chemistry, vol. 267, No. 36, Dec. 25, 1992, pp. 26031-26037.
Takahashi et al., “Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis”, Cancer Research 54, 4233-4237, Aug. 1, 1994.
Berkman et al., “Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms”, The Journal of Clinical Investigation, Inc., vol. 91, Jan. 1993, pp. 153-159.
Brown et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract”, Cancer Research 53, 4727-4735, Oct. 1, 1993.
Olson et al., “Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries”, Cancer Research 54, 276-280, Jan. 1, 1994.
Toi et al., “Association of Vascular Endotheiial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse Breast Cancer”, Jpn. J. Cancer Res., 85, 1045-1049, Oct. 1994.
Kondo et al., “Vascular Endothelial Growth Factor/Vascular Permeabiiity Factor is Detectable in the Sera of Tumor-Bearing Mice and Cancer Patients”, Biochimica et Biophysica Acta 1221 (1994) pp. 211-214.
Aiello et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinai Disorders”, The New England Journal of Medicine, vol. 331, No. 22, pp. 1480-1487, Dec. 1, 1994.
Fava et al., “Vascular Permeability Factor/Endothelial Growth Factor (VPE-VEGF): Accumulation and Expression in Human Synovial Fluids and Rheumatoid Synovial Tissue”, J. Exp. Med. vol. 180, Jul. 1994, pp. 341-346.
Matthews et al., “A Receptor Tyrosine Kinase cDNA Isolated from a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage toc-kit”, Proc. Natl. Acad. Sci. USA, vol. 88, pp. 9026-9030, Oct. 1991 Biochemistry.
Terman et al., “Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor”, Biochemical and Biophysical Research Communications, vol. 187, No. 3, 1992, pp. 1579-1586, Sep. 30, 1992.
Quinn et al., “Fetal Liver Kinase 1 is a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 7533-7537, Aug. 1993 Cell Biology.
Peters et al., “Vascular Endothelial Growth Factor Receptor Expression During Embryogenesis and Tissue Repair Suggests a Role in Endothelial DIfferentiation and Blood Vessel Growth”, Proc. Natl. Acad. Sci. USA, vol. 90, pp. 8915-8919, Oct. 1993 Developmental Biology.
Plate et al., “Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human GliomasIn Vivo”, Nature, vol. 359, Oct. 29, 1992, pp. 845-848.
Fong et al., “Role of the Fit-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium”, Nature, vol. 376, Jul. 6, 1995, pp. 66-70.
Sawano et al., “Flt-1 But Not KDR/Flk-1 Tyrosin Kinase Is a Receptor for Placenta Growth Factor, Which is Related to Vascular Endothelial Growth Factor”, Cell Growth & Differentiation, vol. 7, pp. 213-221, Feb. 1996.
Hanai et al., “Detailed Characterization of Reactivities of Anti-Gastric Cancer Monoclonal Antibodies to Carbohydrate Antigen”, A
Hanai Nobuo
Ito Mikito
Kawada Yoko
Nakamura Kazuyasu
Shibuya Masabumi
Andres Janet L.
Gucker Stephen
Kyowa Hakko Kogyo Co. Ltd.
Nixon & Vanderhye P.C.
LandOfFree
Anti-human VEGF receptor FLT-1 monoclonal antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human VEGF receptor FLT-1 monoclonal antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human VEGF receptor FLT-1 monoclonal antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3566413